Overview

Nuclear Medicine or Radiopharmaceuticals Market Introduction

Nuclear Medicine or Radiopharmaceuticals Market is estimated to value over USD 5.7 billion by 2027 end and register a CAGR of over 4.5% during the forecast period 2020 to 2027.

Market research has predicted that the rise of ailments such as Parkinson's, Alzheimer’s, Cancer and Cardiac failure are reasons which have contributed to the nuclear medicine/radiopharmaceuticals market growth in the forecast period. New strides within neurological applications and major shifts in new products by various companies are aiding the demand for the affordability of radiopharmaceuticals. Imaging processes in nuclear medicine are non-invasive and can be used for treating a number of diseases, such as cancers,  neurological disorders and cardiovascular diseases.

Moreover, surplus investment in healthcare, a need for adequate healthcare facilities and the non-invasive aspects of the process are factors that have pushed for the market growth. The radiopharmaceuticals and nuclear medicine markets is further stimulated by innovations in radiotracers and radioisotopes. However, the lack of reimbursement policies, the short life span of radiopharmaceuticals and the stringent policies laid out by governing bodies could pose potential threats to the market on a global scale.  

Nuclear medicine processes provide help in diagnosing diseases with precise and detailed results at an early stage, long before the symptoms occur. Nuclear medicine tests entails less pain and offers information regarding specific organs with very little radiation. This aids the physicians to treat illnesses such as thyroid, cancer and bone metastasis. 

The diagnostics segment has sub-segments that are known as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). The SPECT segment is likely to dominate the radiopharmaceutical/nuclear medicine diagnostics market in the future owing to the reduced costs and greater availability.

The therapeutics segment is further classified into alpha emitters, beta emitters, and brachytherapy isotopes. The beta emitters will be the foremost segment in the radiopharmaceutical therapeutics and nuclear medicine market.

Some of the players operating in the radiopharmaceuticals and nuclear medicine market includes Cardinal Health Inc. Lantheus Medical Imaging Inc., GE Healthcare,  Eczacibasi-Monrol Nuclear Products, IBA Molecular Imaging, Bayer Healthcare, Nordion Inc, Bracco Imaging S.p.A, Advanced Accelerator Applications S.A.

Nuclear Medicine or Radiopharmaceuticals Market Segmentation:

By Type

• Diagnostic Nuclear Medicine
•  Spect Radiopharmaceuticals
•  Tc-99m
•  Tl-201
•  Ga-67
•  I-123
•  Other Spect Isotopes
•  Pet Radiopharmaceuticals
•  F-18
•  Ru-82
•  Other Pet Isotopes
• Therapeutic Nuclear Medicine
•  Alpha Emitters
•  Ra-223
•  Beta Emitters
•  I-131
•  Y-90
•  Sm-153
•  Re-186
•  Lu-177
•  Other Beta Emitters
•  Brachytherapy Isotopes
•  I-125
•  Ir-192
•  Pd-103
•  Cs-131
•  Other Brachytherapy Isotopes

By Application

• Diagnostic Applications
• Spect Applications
•  Cardiology
•  Lymphoma
•  Neurology
•  Thyroid
•  Other Spect Applications
• Pet Applications
•  Oncology
•  Cardiology
•  Neurology
•  Other Pet Applications
• Therapeutic Applications
•  Thyroid
•  Bone Metastasis
•  Lymphoma
•  Endocrine Tumors
•  Other Therapeutic Applications

By Procedural Volume

• Diagnostic Procedures
•  Spect Radiopharmaceuticals
•  Pet Radiopharmaceuticals
• Therapeutic Procedures
•  Beta Emitters
•  Alpha Emitters
•  Brachytherapy Isotopes

By Region

• Europe
• North America
• Asia Pacific
• Rest of the World 

FutureWise Key Takeaways:

•    Growth prospects
•    SWOT analysis
•    Key trends
•    Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the nuclear medicine/pharmaceuticals  market by type, by application, by procedural volume and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, industry-specific restraints and opportunities)
• To forecast and evaluate micro-markets and the overall market
• To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific and the rest of the world
• To record , evaluate and analyze competitive landscape mapping- technological advancements, product launches, expansions and mergers

Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
           1.1. Objectives of the Study 
           1.2. Market Definition 
           1.3. Market Scope 
                   1.3.1. Years Considered for the Study
                   1.3.2. Market Covered
           1.4. Currency 
           1.5. Limitations 
           1.6. Stakeholders 
 2.  Research Methodology 
           2.1. Research Data 
                   2.1.1. Secondary Data
                           2.1.1.1. Key Data from Secondary Sources
                   2.1.2. Primary Data
                            2.1.2.1. Key Data from Primary Sources
           2.2. Market Size Estimation 
           2.3. Market Breakdown and Data Triangulation 
           2.4. Assumptions for the Study  
3. Executive Summary
           3.1. Market Outlook
           3.2. Segment Outlook
           3.3. Competitive Insights
4. Global Nuclear Medicine or Radiopharmaceuticals Market Variables, Trends & Scope
           4.1. Market Lineage Outlook
           4.2. Penetration and Growth Prospect Mapping
           4.3. Industry Value Chain Analysis
           4.4. Cost Analysis Breakdown
           4.5. Technology Overview
           4.6. Regulatory Framework
                 4.6.1. Reimbursement Framework
                 4.6.2. Standards and Compliances
5. Global Nuclear Medicine or Radiopharmaceuticals Market Overview
           5.1. Market Dynamics
                  5.1.1. Market Driver Analysis
                             5.1.1.1. Increasing focus of Nuclear Medicine or Radiopharmaceuticals Companies on Brand Protection
                             5.1.1.2. Untapped Opportunities in Emerging Regions
                  5.1.2. Market Restraint Analysis
                             5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
                  5.1.3. Industry Challenges
                             5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Nuclear Medicine or Radiopharmaceuticals Market Analysis Tools
           6.1. Industry Analysis - Porter’s
                   6.1.1. Supplier Power
                   6.1.2. Buyer Power
                   6.1.3. Substitution Threat
                   6.1.4. Threat from New Entrants
                   6.1.5. Competitive Rivalry
           6.2. Pestel Analysis
                   6.2.1. Political Landscape
                   6.2.2. Environmental Landscape
                   6.2.3. Social Landscape
                   6.2.4. Technology Landscape
                   6.2.5. Legal Landscape
           6.3. Major Deals And Strategic Alliances Analysis
                   6.3.1. Joint Ventures
                   6.3.2. Mergers and Acquisitions
                   6.3.3. Licensing and Partnership
                   6.3.4. Technology Collaborations
                   6.3.5. Strategic Divestments
           6.4. Market Entry Strategies
           6.5. Case Studies
7. Global Nuclear Medicine or Radiopharmaceuticals Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million)
           7.1. Diagnostic Nuclear Medicine
                7.1.1. Spect Radiopharmaceuticals
                         7.1.1.1. Tc-99m
                         7.1.1.2. Tl-201
                         7.1.1.3. Ga-67
                         7.1.1.4. I-123
                         7.1.1.5.  Other Spect Isotopes
                 7.1.2.  Pet Radiopharmaceuticals
                         7.1.2.1.  F-18
                         7.1.2.2. Ru-82
                         7.1.2.3. Other Pet Isotopes
           7.2. Therapeutic Nuclear Medicine
                7.2.1. Alpha Emitters
                         7.2.1.1.  Ra-223
                         7.2.1.2. Beta Emitters
                         7.2.1.3.  I-131
                         7.2.1.4.  Y-90
                         7.2.1.5.  Sm-153
                         7.2.1.6.  Re-186
                         7.2.1.7.  Lu-177
                         7.2.1.8.  Other Beta Emitters
                7.2.2.  Brachytherapy Isotopes
                          7.2.2.1.  I-125
                          7.2.2.2.  Ir-192
                          7.2.2.3.  Pd-103
                          7.2.2.4. Cs-131
                          7.2.2.5. Other Brachytherapy Isotopes
8. Global Nuclear Medicine or Radiopharmaceuticals Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million)
           8.1. Diagnostic Applications
                 8.1.1. Spect Applications
                            8.1.1.1. Cardiology
                            8.1.1.2. Lymphoma
                            8.1.1.3.  Neurology
                            8.1.1.4. Thyroid
                            8.1.1.5. Other Spect Applications
                 8.1.2. Pet Applications
                             8.1.2.1.  Oncology
                             8.1.2.2.  Cardiology
                             8.1.2.3.  Neurology
                             8.1.2.4.  Other Pet Applications
           8.3. Therapeutic Applications
                  8.3.1.  Thyroid
                  8.3.2.  Bone Metastasis
                  8.3.3.  Lymphoma
                  8.3.4.  Endocrine Tumors
                  8.3.5. Other Therapeutic Applications
9. Global Nuclear Medicine or Radiopharmaceuticals Market, By Procedural Volume Historical Analysis and Forecast 2020-2027 (USD Million)
           9.1. Diagnostic Procedures
                 9.1.1. Spect Radiopharmaceuticals
                 9.1.2. Pet Radiopharmaceuticals    
           9.2. Therapeutic Procedures
                 9.2.1.  Beta Emitters
                 9.2.2.  Alpha Emitters
                 9.2.3.
10. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           10.1. Introduction
           10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                     10.2.1. U.S.A
                     10.2.2. Canada
                     10.2.3. Mexico
           10.3. Market Size (USD Million) Forecast for North America 2020-2027 
11. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           11.1. Introduction
           11.2. Regional Market Trends
           11.3. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                     11.3.1. Brazil
                     11.3.2. Venezuela
                     11.3.3. Argentina
                     11.3.4. Rest of Latin America
           11.4. Market Size (USD Million) Forecast for Latin America 2020-2027  
12. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           12.1. Introduction
           12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                     12.2.1. Germany
                     12.2.2. U.K
                     12.2.3. France
                     12.2.4. Italy
                     12.2.5. Spain
                     12.2.6. Russia
                     12.2.7. Poland
                     12.2.8. Switzerland
                     12.2.9. Rest of Western Europe
           12.3. Market Size (USD Million) Forecast for Europe 2020-2027
13. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           13.1. Introduction
           13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                     13.2.1. Japan
                     13.2.2. China
                     13.2.3. Singapore
                     13.2.4. India
                     13.2.5. Australia and New Zealand
                     13.2.6. ASEAN
                     13.2.7. South Korea
                     13.2.8. Taiwan
                     13.2.9. Rest of Asia Pacific
           13.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027
14. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           14.1. Introduction
           14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                     14.2.1. Saudi Arabia
                     14.2.2. UAE
                     14.2.3. South Africa
                     14.2.4. Egypt
           14.3. Market Size (USD Million) Forecast for MEA 2020-2027
15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
           15.1. Cardinal Health Inc.
                     15.1.1. Company Overview
                     15.1.2. Product Portfolio
                     15.1.3. SWOT Analysis
                     15.1.4. Financial Overview
                     15.1.5. Strategic Overview
           15.2. Lantheus Medical Imaging Inc.
                     15.2.1. Company Overview
                     15.2.2. Product Portfolio
                     15.2.3. SWOT Analysis
                     15.2.4. Financial Overview
                     15.2.5. Strategic Overview
           15.3. GE Healthcare
                     15.3.1. Company Overview
                     15.3.2. Product Portfolio
                     15.3.3. SWOT Analysis
                     15.3.4. Financial Overview
                     15.3.5. Strategic Overview
           15.4. Eczacibasi-Monrol Nuclear Products
                     15.4.1. Company Overview
                     15.4.2. Product Portfolio
                     15.4.3. SWOT Analysis
                     15.4.4. Financial Overview
                     15.4.5. Strategic Overview
           15.5 IBA Molecular Imaging
                     15.5.1. Company Overview
                     15.5.2. Product Portfolio
                     15.5.3. SWOT Analysis
                     15.5.4. Financial Overview
                     15.5.5. Strategic Overview
           15.6 Bayer Healthcare
                     15.6.1. Company Overview
                     15.6.2. Product Portfolio
                     15.6.3. SWOT Analysis
                     15.6.4. Financial Overview
                     15.6.5. Strategic Overview
           15.7. Nordion Inc
                     15.7.1. Company Overview
                     15.7.2. Product Portfolio
                     15.7.3. SWOT Analysis
                     15.7.4. Financial Overview
                     15.7.5. Strategic Overview
           15.8. Bracco Imaging S.p.A
                     15.8.1. Company Overview
                     15.8.2. Product Portfolio
                     15.8.3. SWOT Analysis
                     15.8.4. Financial Overview
                     15.8.5. Strategic Overview
           15.9. Advanced Accelerator Applications S.A.
                     15.9.1. Company Overview
                     15.9.2. Product Portfolio
                     15.9.3. SWOT Analysis
                     15.9.4. Financial Overview
                     15.9.5. Strategic Overview
16. FutureWise SME Key Takeaway Points for Client

Tables

Figures